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Triggering of the T3-Ti antigen-receptor complex results in clonal
T-cell proliferation through an interleukin 2-dependent
autocrine pathway
(T-cell clones/monoclonal antibodies/interleukin 2 receptor/growth regulation)

STEFAN C. MEUER*, REBECCA E. HUSSEY*, DOREEN A. CANTRELLt, JAMES C. HODGDON*,
STUART F. SCHLOSSMAN*, KENDALL A. SMITHt, AND ELLIS L. REINHERZ*
*Division of Tumor Immunology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, MA 02115; and tDepartment
of Medicine, Dartmouth Medical School, Hanover, NH 03755

Communicated by H. Sherwood Lawrence, November 3, 1983

Human T-cell clones and anti-T-cell-receptor
ABSTRACT
antibodies (clonotypic) directed at surface receptors for antigen (T3-Ti molecular complex) as well as anti-interleukin 2
(IL-2) and anti-IL-2-receptor antibodies were utilized to investigate the mechanism by which alloantigens or antigen plus
self-major histocompatibility complex (MHC) (i.e., physiologic ligand) trigger specific clonal proliferation. Soluble or Sepharose-bound anti-Ti monoclonal antibodies, like physiologic
ligand, enhanced proliferative responses to purified IL-2 by
inducing a 6-fold increase in surface IL-2 receptor expression.
In contrast, only Sepharose-bound anti-Ti or physiologic ligand triggered endogenous clonal IL-2 production and resulted
in subsequent proliferation. The latter was blocked by antibodies directed at either the IL-2 receptor or IL-2 itself. These
results suggest that induction of IL-2 receptor expression but
not IL-2 release occurs in the absence of T3-Ti receptor crosslinking. Perhaps more importantly, the findings demonstrate
that antigen-induced proliferation is mediated through an autocrine pathway involving endogenous IL-2 production, release, and subsequent binding to IL-2 receptors.

MATERIALS AND METHODS

Recent studies using cloned antigen-specific T lymphocytes
and monoclonal antibodies directed at their various surface
glycoprotein components have led to identification of the human T-cell-antigen receptor as a surface complex comprised
of a clonotypic 90-kilodalton (kDa) Ti heterodimer and the
monomorphic 20/25-kDa T3 molecule (1, 2). Upon binding
to the surface of a clone, monoclonal antibodies to either T3
or its associated unique Ti heterodimer induced rapid loss of
the T3-Ti complex, a process termed modulation, and inhibited all antigen-specific functions of a given clone. However,
at the same time, these antibodies produced a markedly enhanced clonal proliferative response to interleukin 2 (IL-2)containing media (1-3). Moreover, when coupled to the surface of a solid support such as Sepharose, the appropriate
surface-linked anti-Ti and anti-T3 antibodies were able to induce IL-2 secretion and clonal proliferation, analogous to
physiologic ligand (i.e., antigen) itself (4). These findings
suggested that clonal proliferation resulting from triggering
of the T3-Ti antigen receptor might be mediated through the
growth factor IL-2. The latter is a 15-kDa sialoglycoprotein
that interacts with activated T cells through specific membrane receptors distinct from the T3-Ti complex and is
known to induce T-cell growth upon surface binding (5-12).
The present study was performed to examine the relationship between the T-cell-antigen receptor and IL-2-mediated
T-cell growth.

Human T-Cell Clones. The human T-cell clones CT8111,
CT411, and RW17C were obtained from a single donor's peripheral blood mononuclear cells, cloned, and maintained in
culture as described (13, 14). Briefly, the cytotoxic clones
CT8111 and CT411 have a target specificity for class I and class
II alloantigens, respectively, both of which are present on
the Epstein-Barr virus-transformed human lymphoblastoid
B cell line Laz 156 (1, 2, 14, 15). In contrast, RW17C recognizes ragweed antigen E (RWAGE) in the context of an
autologous class II major histocompatibility complex (MHC)
gene product. Moreover, RW17C provides potent help for Bcell IgG secretion (16).
Derivation of Monoclonal Antibodies and Surface Expression of T-Cell Antigens. The clone-specific murine monoclonal antibodies anti-Til, anti-Ti2, and anti-Ti4 and the anti-T3
monoclonal antibodies were obtained from immunizations
with individual T-cell clones as described (1, 2, 16, 17). The
antigens defined by the various anti-Ti antibodies appear as
clonally unique 90-kDa disulfide heterodimers consisting of
41-43 /3 and 49-53 a chains (anti-Til, clone CT8111; anti-Ti2,
clone CT411; and anti-Ti4, clone RW17C) that are associated
with the monomorphic T3 structure. These monoclonal antibodies are not crossreactive. Anti-T3, -T4, -T11, and -Ia
monoclonal antibodies have been described (18-23). Monoclonal antibodies to the IL-2 receptor, termed anti-Tac, and
to human IL-2, termed DMS-1, were produced as described
(9, 10, 12).
The reactivity of clonal populations with individual monoclonal antibodies was determined by means of indirect immunofluorescence on an Epics V cell sorter (Coulter) (23),
and the number of binding sites was quantitated by flow cytometry as described (2, 24). Modulation studies were performed as described (1).
Purification and Surface Coupling of Monoclonal Antibodies. Anti-Til, anti-Ti2, and anti-Ti4 were individually purified
from malignant ascites by using protein A-Sepharose (Pharmacia) (25). In each case, 5 mg of purified antibody was coupled to 1 ml of swollen CNBr-activated Sepharose 4B beads.
Functional integrity of the surface-bound monoclonal antibodies was confirmed by immunoprecipitations from 1251_
surface-labeled T-cell clones.
Proliferative Assays. Proliferative in vitro assays were performed in triplicate in a standard culture system with 96-well
round-bottom microtiter plates (Costar, Cambridge, MA). In
the case of CT411 and CT8111, 3 x 104 cloned cells were incubated with 3 x 104 irradiated Laz 156 cells, medium, or 0.5
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units of affinity-purified human IL-2 per ml. The homogeneity of the latter preparation was demonstrated by the fact
that it appeared as a single protein on NaDodSO4/PAGE and
reverse-phase liquid chromatography (12). RW17C was incubated at 3 x 104 cells per well together with autologous antigen-presenting cells (APC; 5 x 103 per well) and RWAGE
(Worthington) (10 gg/ml) or medium or human IL-2 (0.5
unit/ml). After 24 hr, the various cultures were individually
pulsed with 1 gCi (1 Ci = 37 GBq) of [3H]Thd (Schwartz/
Mann), harvested 18 hr later on a MASH II apparatus (M. A.
Bioproducts, Walkersville, MD), and subsequently measured in a Packard scintillation spectrometer. Standard deviations in these experiments were <18%.
Determination of IL-2 Secretion by T-Cell Clones. To quantitate the amount of IL-2 secreted by individual clones after
stimulation, a murine T-cell proliferative assay was used.
Specifically, 5000-rad-irradiated cloned human T lymphocytes (5 x 104 per well) and one or another stimulus were
added to 5 x 104 murine T lymphoblasts previously induced
with phytohemagglutinin. After 18 hr of culture, individual
wells were pulsed for 24 hr with 1 ,Ci of [3H]Thd, mashed,
and assayed for radioactivity as above. A standard curve obtained with serial dilutions of purified human IL-2 was utilized to quantitate the amounts of lymphokine produced by
the various T-cell clones.

RESULTS
To investigate the molecular basis of enhanced proliferation
to IL-2 after T3-Ti modulation, we used three antigen-specific human T-cell clones and a series of anti-clonotypic
monoclonal antibodies in conjunction with a homogeneous
IL-2 preparation and anti-Tac (9, 10) and DMS-1 (12) monoclonal antibodies. The two human cytotoxic T-cell clones
CT411 and CT8,11 (derived from the T4+ and T8+ T-cell subpopulations, respectively) and the noncytotoxic RWAGEspecific T4+-inducer T-cell clone RW17C proliferated in vitro to purified IL-2 (0.5 unit/ml; unmodulated) (Table 1).
After modulation with their specific anti-clonotypic monoclonal antibodies, anti-Til (CT8,11), anti-Ti2 (CT41I), or antiTi4 (RW17C), each of the three clones demonstrated a markedly enhanced [3H]Thd uptake (200-300% enhanced), consistent with earlier findings where stimulation was obtained
by IL-2-containing T cell-conditioned media (1-3). Moreover, the homogeneous IL-2 preparation utilized here ruled
out the possibility that the enhanced proliferation to conditioned media observed previously was due to a mitogenic
stimulus other than IL-2. Note that while much of the increase in [3H]Thd incorporation in response to IL-2 after
anti-Ti modulation can be accounted for on the basis of a
larger fraction of cells in the S phase of cell cycle, it is also
possible that the generation time of the cells is shortened.
The IL-2-driven proliferative responses of these clones in
either an unmodulated or anti-Ti-modulated state could be
abrogated by anti-Tac antibodies (.90% inhibition). In contrast, monoclonal antibodies to a constant portion of the hu-
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man Ia antigen that, like Tac, appears on activated T cells
did not diminish IL-2-mediated clonal proliferation. Both the
failure to block this response with anti-Ia and the fact that
anti-Tac did not influence the clonal cytotoxic effector function (data not shown) made it unlikely that abrogation of
clonal proliferation was simply due to a general inhibition of
clonal activity. Table 1 also shows that IL-2-induced proliferation could be substantially diminished (>60%) by the
anti-DMS-1 antibody previously shown to be directed at human IL-2 (12).
The above results unequivocally demonstrated that IL-2
mediated the enhanced proliferation seen subsequent to antigen receptor modulation. However, the basis for this increased clonal responsiveness was not known. Because individual clones could not be induced to proliferate by anti-Ti
modulation alone, it seemed unlikely that the increase in proliferation of the anti-Ti modulated clone was due to secretion
of endogenous lymphokine. Rather, it was more probable
that anti-Ti modulation enhanced the number of surface IL-2

receptors.
To test this notion, the various clonal populations were

incubated with one or another anti-clonotypic monoclonal
antibody for 18 hr at 37°C; subsequently, IL-2 receptors
were quantitated by means of immunofluorescence on an
Epics V cell sorter (Fig. 1). Given the known characteristics
of the log amplifier of the Epics V and the existing calibration curve relating linear and log fluorescence (based on
mean channel fluorescence of fluorescent peaks) (24), it was
possible to quantitate the number of binding sites per cell for
the various anti-T-cell antibodies. In addition to Tac, surface
expression of T3, T4, and T11 antigens was evaluated.
Untreated (media preincubated) RW17C cells expressed
45,000, 105,000, 187,000, and 10,500 binding sites per cell of
T3, T4, T11, and Tac antigens, respectively (Table 2; Fig. 1,
row A). The numbers of binding sites for T3 and T4 were
similar to those obtained previously on other clones when
determined either by means of quantitative fluorescence or
by using 125I-labeled monoclonal antibodies (2). Note that
the number of binding sites for anti-Tac on RW17C was considerably lower than the other surface glycoproteins and remained at this level or less as long as the cells were cultured
in IL-2-containing media without further antigenic stimulation (see below). In fact, other studies (26) indicate that in
the absence of mitogenic or antigenic stimulation, IL-2 receptor expression diminishes on IL-2-dependent T-cell
clones over time.
After modulation (Fig. 1, row B) with anti-Ti4 (or anti-T3
by soluble antibody or antibody coupled to Sepharose beads;
data not shown), however, there was a 6-fold increase in the
number of IL-2 receptor binding sites as measured by antiTac (62,000). In contrast, anti-Ti4 modulation was associated
with a 75% reduction in the number of T3 binding sites
(11,500), consistent with previous data indicating that the T3
and Ti surface structures are linked to one another in the
membrane of human T cells (1, 2). Unlike T3, the number of

Table 1. In vitro proliferative responses of various clones to IL-2 after modulation with clone-specific monoclonal antibodies (Anti-Til,2,4)
CT411
RW17C
CT81I
Unmodulated
Unmodulated
Anti-Ti2-modulated
Unmodulated
Anti-Ti4-modulated
Anti-Til-modulated
Medium
124
562
653
355
266
497
IL-2
3393
7359
4940
12,737
8154
25,718
IL-2 + anti-Tac
128
384
325
140
815
870
IL-2 + anti-Ia
2785
7006
4563
12,541
7937
25,133
IL-2 + DMS-1
NT
2941
1700
4,383
2906
8,851
and
CT411,
RW17C
were
individually
incubated
with
one
or
another
clone-specific
anti-Ti
monoclonal
antibody
or
medium.
SubseCT8III,
quently, proliferative responses to purified human IL-2 (0.5 unit/ml) were determined. Final dilutions or concentrations of monoclonal antibodies were: anti-Tac, 1:750 (ascites in medium); anti-Ia 1:500 (ascites in medium); DMS-1, 200 Mg of purified antibody per ml. Values are given as
cpm of [3H]Thd uptake and represent the means of triplicate cultures. Standard deviations were <18%. NT, not tested.
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FIG. 1. Changes in cell surface expression of T-cell membrane
antigens after triggering of the antigen receptor. RW17C cells were
incubated for 18 hr with the following stimuli: medium (row A), antiTi4 (final dilution, 1:250) (row B), autologous APC with RWAGE (10
,ug/ml) (row C), autologous APC with tetanus toxoid (20,ug/ml)
(row D), and allogeneic APC with RWAGE (10
lg/ml) (row E). Subsequently, cells were washed and analyzed by means of indirect immunofluorescence with saturating concentrations of monoclonal
antibodies and fluorescein isothiocyanate-conjugated F(ab')2 fragment of goat anti-mouse Ig on an Epics V cell sorter (final dilutions
of monoclonal antibodies: anti-T3A, 1:500; anti-T4A, 1:1000; antiT11, 1:1000; anti-Tac, 1:750). The negative control consisted of incubating the various cell populations with J5, 1:500 dilution, a monoclonal antibody (IgG2 isotype) specific for CALLA antigen and fluorescein isothiocyanate-conjugated goat anti-mouse F(ab')2. Note
that the threshold for detection in this fluorescence system is 24000
sites per cell.

T4 molecules remained unaffected by this process, and the
T11 surface expression increased by <50%. Given these
findings and the above functional data, it would appear that
the enhanced in vitro proliferative response to IL-2 by antiTi or anti-T3 modulated T-cell clones is a consequence of the
increased density of IL-2 receptors.
Because anti-clonotypic monoclonal antibodies appear to
recognize the same antigen binding site as the natural ligand
for Ti (4, 16), it was of interest to determine whether the
latter would have similar effects. There was a strong increase in anti-Tac binding sites (61,000 vs. 11,000) and a reduction in T3 surface expression (24,000 vs. 45,000) when
RW17C was preincubated with RWAGE and autologous
APC (Fig. 1, row C; Table 2). Thus, it appears that this
cloned population is fully activated vis-a'-vis IL-2 receptor
expression only after antigenic receptor triggering. Note that
the number of T3 binding sites (i.e., 24,500) is overestimated
by this analysis because the discrete anti-T3 unreactive
(T3) T-cell population (Fig. 1, row C) was excluded from
the calculation. Although the reason for the bimodal reactivity of anti-T3 on the MHC/antigen-triggered RW17C is not
known, it is most likely a consequence of ligand-T3-Ti-receptor binding and cell proliferation.
Perhaps more importantly, Fig. 1 demonstrates that IL-2
receptor expression and T3 modulation were critically dependent on a unique combination of MHC-restricting element and antigen. Thus, a mixture of autologous APC with
the irrelevant antigen tetanus toxoid (Fig. 1, row D) or, alternatively, allogeneic APC with the relevant antigen RWAGE
(Fig. 1, row E) did not induce these membrane changes. The
present data confirm previous results indicating that RW17C
recognized RWAGE only in the context of autologous class
II MHC gene products (16) and that the anti-clonotypic
monoclonal antibody anti-Ti4 reacted with the binding structure for antigen plus MHC because it induced identical phenotypic membrane changes.
In addition to induction of IL-2 receptors, other studies
indicated that cell-bound antigen (e.g., alloantigen in the
case of CT411 and CT8,11) triggered clonal proliferation and
lymphokine production (4). The same effects also were ob-
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Table 2. Changes in surface expression of T-cell differentiation
antigens on clone RW17C as a consequence of
T-cell-receptor triggering
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T4

T11

Tac

45,000
11,500
24,500

105,000
187,000
10,500
105,000
270,000
62,000
Ag/MHC
112,000
255,000
61,000
RW17C cells were incubated with medium, monoclonal antibody
anti-Ti4 (1:250), or RWAGE with autologous APC [antigen (Ag)/
MHC] for 18 hr prior to the determination of T3, T4, T11, and Tac
binding sites by means of quantitative indirect immunofluorescence.
served with anti-clonotypic antibodies when the latter were
coupled to a solid support but were not induced by anti-clonotypic monoclonal antibodies in soluble form (4). Taken together, these findings supported the notion that Ti receptor
crosslinking, although not required for IL-2 receptor expression, was an essential prerequisite for induction of clonal
proliferation.

That triggering of the Ti structure should result in endogeIL-2 production, enhanced IL-2 receptor expression,
and clonal proliferation appeared more than coincidental and
suggested that stimulation of clonal proliferation through
antigen receptor triggering was due to release and subsequent binding of endogenous IL-2-i.e., an autocrine mechanism. If this were the case, then one would anticipate that
clonal proliferation after antigen receptor triggering and
crosslinking could be inhibited by anti-IL-2 or anti-IL-2receptor antibodies. To test that possibility, CT8111 and
RW17C were incubated with the appropriate physiologic ligands (Laz 156 or RWAGE in the context of autologous
APC, respectively), and the anti-clonotypic antibodies antiTil and anti-Ti4 coupled to Sepharose beads, or the same
antibodies in soluble form. RW17C and CT81,1 produced IL2 (0.7-1.0 and 0.25-0.4 unit/ml, respectively) and mounted
strong proliferative responses upon incubation with either of
the former two stimuli in the absence of exogenous lymphokines (29,659/18,509 cpm and 9,211/6,985 cpm, respectively) (Table 3). In contrast and as expected, soluble anti-clonotypic antibodies had no mitogenic effect. Importantly, antiTac but not antibodies to other T-cell activation structures
(anti-Ia) inhibited the [3H]Thd uptake in all cases (inhibition
250%). In addition, DMS-1 antibody diminished in vitro proliferation as well, although the magnitude of the effect was
not as pronounced as that with anti-Tac (25-50%). The less
marked inhibitory effect of DMS-1 antibody may relate to
the greater affinity of surface IL-2 receptors for the IL-2 ligand than DMS-1. Nevertheless, these findings make it clear
that clonal proliferation is due to release and subsequent
binding of IL-2 to its surface receptor. It should be noted
that, in contrast to its inhibitory effect on proliferation, antiTac did not influence the IL-2 release mechanism (data not
shown). Thus, IL-2 production in the presence of anti-Tac
was not diminished after Ti triggering. This result further
supported the view that the anti-Tac antibody specifically
blocks the binding of IL-2 to its receptor (10, 11).
nous

DISCUSSION

To investigate some of the molecular mechanisms underlying T-cell proliferation after triggering of antigen receptors,
we utilized three antigen-specific human T-cell clones,
CT8111, CT4,1, and RW17C (1, 2, 14, 16), in conjunction with
anti-clonotypic, anti-Tac, and DMS-1 monoclonal antibodies. The results clearly demonstrated that there was a functional linkage between antigen receptor and IL-2 receptor on
all three of these clones. Specifically, soluble anti-T3 or antiTi antibodies, like physiologic ligand, induced a 6-fold increase in IL-2 receptors. Moreover, when these antibodies
were bound to Sepharose beads, they induced IL-2 secretion
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Table 3. IL-2 secretion and blocking of proliferation by monoclonal antibodies after antigen-receptor triggering
Stimuli of clone RW17C
Stimuli of clone CT811I
Monoclonal Ab Laz 156 Anti-Ti1-Sepharose Anti-Ti1 (soluble) Ag/MHC Anti-Ti4-Sepharose Anti-Ti4 (soluble)
IL-2 produced, units/ml
0.7
<0.05
0.4
1.0
0.25
None (medium)
<0.05

Proliferation, cpm
515
9211
6985
None (medium) 29,659
232
18,509
458
4219
2026
NT
Anti-Tac
2,623
3,969
479
7829
5308
NT
DMS-1
14,333
14,382
Anti-Ia
468
9303
6426
28,281
NT
18,740
Cloned T cells (3 x 104) were incubated with the following stimuli in the presence or absence of monoclonal antibodies.
Stimuli of clone CT81: 3 x 104 Laz 156 cells (irradiated with 5000 rad); anti-Til-Sepharose (predetermined optimal concentration); and anti-Til (soluble), final dilution of 1:500 ascites in medium. Stimuli for clone RW17C: 3 x 103 autologous APC
with RWAGE (10 Ag/ml); anti-Ti4-Sepharose (predetermined optimal concentration); and anti-Ti4 (soluble), final dilution
of 1:500 ascites in medium. Final dilutions or concentrations of antibodies: anti-Tac, 1:750 (ascites in medium); DMS-1, 200
,ug of purified antibody per ml; and anti-Ia, 1:500 (ascites in medium). Values represent means of triplicate cultures and are
given as cpm of [3H]Thd uptake. Standard deviations were <18%. NT, not tested.

and clonal proliferation analogous to antigen. That the latter
response was mediated by IL-2 was evident from the finding
that either monoclonal anti-Tac or DMS-1 antibodies
blocked clonal proliferation following T3-Ti triggering.
The induction of IL-2 receptors occurred as a discrete
event in and of itself and did not appear to require Ti crosslinking (or more precisely, crosslinking of more than two receptors, if one assumes that the antigen receptor is univalent) because it could be mediated by binding of soluble antiTi monoclonal antibody to the clone's surface. In contrast,
production and release of IL-2 and subsequent clonal proliferation did not occur in the absence of apparent receptor
crosslinking initiated by surface-bound antigen on the stimulator cells or anti-Ti coupled to Sepharose. Note that we cannot formally rule out the possibility that Sepharose-bound
antibodies may be acting on these cloned T cells independently of any crosslinking effect, for instance, either by increasing the avidity of the antibody for the receptor or interacting with other surface molecules unrelated to T3-Ti. Such
possibilities seem remote because three antibodies to the Ti

structure of CT411, regardless of their isotype, have identical
functional effect when coupled to Sepharose 4B, and yet
none of these soluble anti-Ti antibodies in combination with
an uncoupled bead triggers IL-2 release or clonal proliferation (ref. 4; data not shown). The identity of the phenotypic
changes induced by anti-Ti anti-receptor antibodies and antigen/MHC on RW17C provides further support for the notion
that the Ti complex is the receptor for both antigen and
MHC.
Therefore, it appears that T-cell proliferation occurs as a
series of complex and precisely orchestrated events as outlined in Fig. 2. Resting T-cell clones or T cells express few or
no IL-2 receptors but display a maximal number of surface
antigen receptors (stage 1). However, T3-Ti receptor triggering by antigen plus MHC gene product of the appropriate
haplotype or Sepharose-bound anti-clonotypic monoclonal
antibodies results in modulation of the T3-Ti complex (stage
2), thus diminishing the number of surface antigen receptors
and rapidly inducing surface IL-2 receptor expression (stage
3). Furthermore, such activation also leads to endogenous

2

I.
0

V
..

-

0

FIG. 2. Schematic model of T-cell proliferation mediated by an IL-2-dependent autocrine mechanism. Stage 1: resting T cells or T-cell
clones express few or no IL-2 receptors (uf) while reciprocally displaying a maximal number of antigen receptors (v). Stage 2: T3-Ti triggering
by antigen/MHC-restricting element (t) or surface-bound anti-T-cell-receptor antibodies (t) results in T3-Ti modulation, thus reducing the
number of surface antigen receptors and rapidly inducing surface IL-2 receptor expression. Stage 3: this event appears to occur prior to IL-2
secretion itself because IL-2 receptor expression can be observed 2-4 hr after Ti-T3 triggering, whereas IL-2 is not detectable in culture
supernatants until at least 10-12 hr later. Stage 3 also can be achieved with anti-Ti or anti-T3 monoclonal antibodies in soluble form. Stage 4:
activation via Ti-T3 leads to production and secretion of endogenous IL-2 (o) and subsequent binding to its own IL-2 receptors. Stage 5: once a
critical density of occupied IL-2 receptors is achieved, DNA synthesis and mitosis occur. Finally, in the absence of additional antigenic
stimulation, there is reexpression of the surface T3-Ti antigen receptor complex (stage 1).
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IL-2 production, secretion, and subsequent binding to IL-2
receptors on the same clones (stage 4). Once a critical number of IL-2 receptors have bound IL-2, DNA synthesis and
cell mitosis occur (stage 5). Finally, in the absence of continued antigenic stimulation, there is reexpression of the surface T3-Ti antigen-receptor complex and, reciprocally, a reduction in the number of IL-2 receptors (stage 1).
The present set of findings is in agreement with recent
studies with lectin-stimulated peripheral blood T lymphocytes in which it was shown that IL-2 receptor expression
occurred during the G1 phase of cell cycle and preceded
DNA synthesis (26). Moreover, the correlation of IL-2 receptor levels with the proportion of cells in active cycle emphasized the importance of antigen receptor triggering on IL2 responsiveness, especially when IL-2 concentrations become limiting. In addition, induction of IL-2 receptors by
antigenic stimulation as shown here provides a rational basis
for the empiric observations that IL-2-mediated clonal expansion in vitro is facilitated by repetitive antigenic stimulation. In this regard, recent studies have demonstrated that
loss of IL-2 responsiveness is not secondary to down regulation of IL-2 receptors per se but rather secondary to lack of
repetitive antigenic challenge (26).
The view that is emerging regarding the relationship of the
T3-Ti antigen receptor to the IL-2 receptor points to a mechanism whereby external stimuli-i.e., antigen-direct the
magnitude and extent of T-cell clonal proliferation by means
of the IL-2 hormone-receptor system. Immunologic specificity is ensured by the antigen dependence of the IL-2 receptor expression, and yet the reciprocal appearance of T3Ti and IL-2 receptors presumably leaves the cell in a state of
responsiveness to either the hormone or antigen ligand.
However, the transient expression of the IL-2 receptors
themselves serves as a fail-safe system to eliminate any possibility of uncontrolled growth through an IL-2-dependent
mechanism. Whether alteration of this mechanism results in
tumor growth in vivo as suggested by studies on continuously growing, IL-2-producing primate tumor lines of T-cell lineage remains to be determined but appears likely (27).
The present construct clearly implies that T-cell proliferation is mediated through an autocrine network in which antigen-receptor triggering leads to IL-2 receptor expression,
IL-2 production, IL-2 release, and subsequent IL-2 receptor
occupancy, which ultimately promotes cell division. Note
that it does not necessarily follow that all T cells produce and
respond to their own IL-2. In fact, one would predict that the
failure of certain cells to proliferate to antigen occurs as a
consequence of their inability to produce sufficient amounts
of endogenous IL-2, although such cells would, in all likelihood, be triggered to express IL-2 receptors. Furthermore,
even for IL-2-producing T cells, exogenous sources of IL-2
would amplify clonal proliferation. However, the present results are clearly different than anticipated from the conventional endocrine notion that suggests that one cell type produces IL-2 while a different one responds to it.
The above findings stress the central linkage of the T-cell
receptor to the IL-2 hormonal system and the critical role of
the latter in T-cell proliferation. The present reagents provide an excellent set of probes with which to evaluate the
mechanisms that regulate and maintain physiologic T-cell
growth. In addition, they should provide important insights
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into aberrations of these control mechanisms that could underlie malignant transformation within the T-cell lineage.
This work was supported by National Institutes of Health Grants
1 RO1 Al 19807 01, RO1 NS 17182, CA 17643, CA 17323, CA 23108,
and CA 26273 and Grant CH 167 from the American Cancer Society.
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